Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nepal Medical Association
2011-03-01
|
| Series: | Journal of Nepal Medical Association |
| Online Access: | http://jnma.com.np/jnma/index.php/jnma/article/view/44 |
| Summary: | Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese experiences should provide new information for the treatment of chronic hepatitis C.
Keywords: Direct-acting antiviral agents (DAA), HCV, pegylated interferon, ribavirin, standard of care (SOC ).
|
|---|---|
| ISSN: | 0028-2715 1815-672X |